1. Economics of biological therapies;Kelly;BMJ.,2009
2. Public biotech 2012—the numbers;Huggett;Nat Biotechnol.,2013
3. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf [consultado 29 Ago 2014].
4. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf [consultado 29 Ago 2014].
5. Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS) [consultado 29 Ago 2014]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02016105?term=biosimilar+adalimumab&rank=1